Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (EE-ASI-1): A Phase 1a Study of Gold Nanoparticles Administered Intradermally by Microneedles to Deliver Immunotherapy With a Proinsulin Derived Peptide in Type 1 Diabetes

Trial Profile

Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (EE-ASI-1): A Phase 1a Study of Gold Nanoparticles Administered Intradermally by Microneedles to Deliver Immunotherapy With a Proinsulin Derived Peptide in Type 1 Diabetes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs MTX 102 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man
  • Acronyms EE-ASI-1
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 30 Sep 2016 According to a Midatech Pharma media release, results from this study are expected in 2017. This trial is a part of a four-year European Commission-supported program EE-ASI into researching beta cell preservation using Antigen Specific Immunotherapy (ASI) via GNP technology.
    • 30 Sep 2016 Status changed from planning to recruiting, according to Midatech Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top